Advertisement
Screener

ORGANOGENESIS HOLDINGS INC. (ORGO) Number of Reportable Segments

2.8 / 5 stars · 68/120 Roast Me

ORGANOGENESIS HOLDINGS INC. Number of Reportable Segments

ORGANOGENESIS HOLDINGS INC. (ORGO) reported Number of Reportable Segments of 1 Segments for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Segment Reporting

us-gaap:NumberOfReportableSegments · last filed 2026-08-06

  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segments, a 0.00% change year-over-year.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segments, a 0.00% change year-over-year.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for the quarter ending 2024-03-31 was 1.00 Segments, a 0.00% change year-over-year.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for the quarter ending 2023-03-31 was 1.00 Segments, a 0.00% change year-over-year.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for fiscal 2025 was 1.00 Segments, a 0.00% change from fiscal 2024.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for fiscal 2024 was 1.00 Segments, a 0.00% change from fiscal 2023.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for fiscal 2023 was 1.00 Segments, a 0.00% change from fiscal 2022.
  • ORGANOGENESIS HOLDINGS INC. number of reportable segments for fiscal 2022 was 1.00 Segments, a 0.00% change from fiscal 2021.
Period endNumber of Reportable Segments 3 monthNumber of Reportable Segments 6 monthNumber of Reportable Segments 9 monthNumber of Reportable Segments 12 month
2026-06-301.00 Segments
10-Q · filed 2026-08-06
2026-03-311.00 Segments
10-Q · filed 2026-05-07
2025-12-311.00 Segments
10-K · filed 2026-02-26
2025-09-301.00 Segments
10-Q · filed 2025-11-06
2025-06-301.00 Segments
10-Q · filed 2025-08-07
2025-03-311.00 Segments
10-Q · filed 2025-05-08
2024-12-311.00 Segments
10-K · filed 2025-02-27
2024-09-301.00 Segments
10-Q · filed 2024-11-12
2024-06-301.00 Segments
10-Q · filed 2024-08-08
2024-03-311.00 Segments
10-Q · filed 2024-05-09
2023-12-311.00 Segments
10-K · filed 2024-02-29
2023-09-301.00 Segments
10-Q · filed 2023-11-09
2023-06-301.00 Segments
10-Q · filed 2023-08-09
2023-03-311.00 Segments
10-Q · filed 2023-05-10
2022-12-311.00 Segments
10-K · filed 2023-03-01
2022-09-301.00 Segments
10-Q · filed 2022-11-09
2022-06-301.00 Segments
10-Q · filed 2022-08-09
2022-03-311.00 Segments
10-Q · filed 2022-05-10
2021-12-311.00 Segments
10-K · filed 2022-03-01
2021-09-301.00 Segments
10-Q · filed 2021-11-09
2021-06-301.00 Segments
10-Q · filed 2021-08-09
2021-03-311.00 Segments
10-Q · filed 2021-05-11
2020-12-311.00 Segments
10-K · filed 2021-03-16
2019-12-311.00 Segments
10-K · filed 2020-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50